Lupin launches generic Atovaquone Oral Suspension USP in the US

Lupin launches generic Atovaquone Oral Suspension USP in the US

Pharma major Lupin announced the launch of Atovaquone Oral Suspension USP, 750 mg/5 mL having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Atovaquone Oral Suspension USP, 750 mg/5 mL is the generic equivalent of Glaxosmithkline LLC’s Mepron® oral suspension 750 mg/5 mL. It is indicated for the prevention of Pneumocystis jirovecii pneuomonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprimsulfamethoxazole (TMP-SMX). It is also for the treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX.

Atovaquone Oral Suspension USP, 750 mg/5 mL had annual sales of approximately USD 119 million in the US (IQVIA MAT September 2018). Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin announced that it has received approval for its Budesonide Inhalation Suspension, 0.5 mg/2 mL Single-Dose Ampules from the United States Food and Drug Administration (FDA) to market a generic version of AstraZeneca Pharmaceuticals LP’s (AstraZeneca) Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL. Lupin’s Budesonide Inhalation Suspension, 0.5 mg/2 mL Single-Dose Ampules is the generic version of AstraZeneca’s Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL. It is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. Budesonide Inhalation Suspension, 0.5 mg/2 mL Single-Dose Ampules had annual sales of approximately USD $474.5 million in the US (IQVIA MAT September 2018).

Lupin is the 13th largest generics pharmaceutical company in terms of market capitalization (30th September 2018, Bloomberg) and the 8th largest generics pharmaceutical company in terms of revenues (30th June 2018, Bloomberg LTM) globally. The Company is the 3rd largest pharmaceutical player in the US by prescriptions for the Total Market (IQVIA MAT September 2018); 3rd largest Indian pharmaceutical company by global revenues (30th June 2018, Bloomberg LTM); 6th largest generic pharmaceutical player in Japan (IQVIA MAT September 2018) and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT September 2018).